<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="46">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01908010</url>
  </required_header>
  <id_info>
    <org_study_id>M13-080</org_study_id>
    <nct_id>NCT01908010</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors</brief_title>
  <official_title>A Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate safety, tolerability and pharmacokinetics of ABT-354 in up to 20&#xD;
      male and female subjects, between 55 to 90 years of age with mild to moderate Alzheimer's&#xD;
      disease on stable doses of acetylcholinesterase inhibitors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, placebo-controlled, randomized, multiple-dose, multicenter study. Up&#xD;
      to 20 male and female subjects with mild to moderate Alzheimer's disease (AD) who are taking&#xD;
      stable doses of acetylcholinesterase inhibitors will be enrolled in this study. Within 28&#xD;
      days prior to study drug administration, subjects will be screened based on National&#xD;
      Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and&#xD;
      Related Disorders Association (NINCDS/ADRDA) criteria for probable AD, Mini-Mental State&#xD;
      Examination (MMSE) and Modified Hachinski Ischemic Scale (MHIS) scores, medical history,&#xD;
      physical examination, neurological examination, vital signs, ECG, laboratory tests and&#xD;
      response to Columbia-Suicide Severity Rating Scale (C-SSRS).&#xD;
&#xD;
      The study will be performed in two groups of 10 subjects each. In each group of 10 subjects,&#xD;
      7 subjects will be randomly assigned to receive ABT-354 and 3 subjects to receive matching&#xD;
      placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vital signs</measure>
    <time_frame>Up to Day 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG (electrocardiogram)</measure>
    <time_frame>Up to Day 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Neurological exam</measure>
    <time_frame>Up to Day 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory tests</measure>
    <time_frame>Up to Day 10</time_frame>
    <description>Hematology, Chemistry, Urinalysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subject with adverse events</measure>
    <time_frame>Up to Day 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>C-SSRS (Columbia-Suicide Severity Rating Scale)</measure>
    <time_frame>Up to Day 10</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters</measure>
    <time_frame>Up to Day 10</time_frame>
    <description>Cmax, Cmin, Tmax, AUC, t-1/2, CL/F</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Group 1, low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-354</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2, high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-354</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-354</intervention_name>
    <description>ABT-354 Low Dose</description>
    <arm_group_label>Group 1, low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-354</intervention_name>
    <description>ABT-354 High Dose</description>
    <arm_group_label>Group 2, high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Group 1, low dose</arm_group_label>
    <arm_group_label>Group 2, high dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Meets the National Institute of Neurological and Communicative Disorders and&#xD;
             Stroke/Alzheimer's Disease and Related Disorders Association criteria for probable&#xD;
             Alzheimer's Disease&#xD;
&#xD;
          -  Has a Mini-Mental State Examination total score of 16 to 26, inclusive, at Screening&#xD;
&#xD;
          -  Has a Modified Hachinski Ischemia Scale score of â‰¤ 4 at Screening&#xD;
&#xD;
          -  On a stable dose of - donepezil, galantamine or rivastigmine for at least 30 days&#xD;
             prior to study drug administration&#xD;
&#xD;
          -  Has had a computerized tomography or magnetic resonance imaging scan, interpreted by a&#xD;
             radiologist or neurologist, within 36 months prior to randomization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Receipt of any depot drug by injection within 30 days prior to study drug&#xD;
             administration&#xD;
&#xD;
          -  Receipt of an investigational product within a time period equal to 10 half-lives, if&#xD;
             known, or within 6 weeks prior to study drug administration&#xD;
&#xD;
          -  History of any significant neurological disease other than Alzheimer's Disease&#xD;
&#xD;
          -  History of significant sensitivity or allergy to multiple drugs based on medical&#xD;
             records and/or the opinion of the investigator&#xD;
&#xD;
          -  Significant current - suicidal ideation within 1 month prior to study drug&#xD;
             administration as evidenced by answering &quot;yes&quot; to questions 4 or 5 on the suicidal&#xD;
             ideation portion of the Columbia-Suicide Severity Rating Scale completed at Screening&#xD;
             or any history of suicide attempts&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerard Marek, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 106999</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 106998</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 107000</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>July 23, 2013</study_first_submitted>
  <study_first_submitted_qc>July 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2013</study_first_posted>
  <last_update_submitted>December 9, 2013</last_update_submitted>
  <last_update_submitted_qc>December 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

